Fig. 2.

eIF4F inhibition promotes ERK activation in melanoma cells. Western blot analysis of A375 and MelJuso cells after 20 h treatment with increasing concentrations of small-molecule eIF4F inhibitors. (A) eIF4A inhibitor Rocaglamide A (RocA) or (B) eIF4E-eIF4G disruptor, 4E1RCat. The activity of MEK and ERK is represented by the ratio of phospho-MEK and phospho-ERK (p-MEK, p-ERK) to vinculin levels. Vinculin served as a loading control. The control samples (CTRL) were treated with an equivalent volume of the vehicle (DMSO). The upper index letters refer to the corresponding loading control detected on the same membrane.